Last reviewed · How we verify
Allogeneic Mesenchymal Precursor Cells
Allogeneic Mesenchymal Precursor Cells is a Cell therapy Small molecule drug developed by Mesoblast, Ltd.. It is currently in Phase 2 development.
Mesenchymal precursor cells modulate immune responses and reduce inflammation through paracrine signaling and cell-to-cell interactions.
Allogeneic Mesenchymal Precursor Cells are a type of somatic cell supplemental therapy used to treat various conditions, including Hypoplastic Left Heart Syndrome, Atrioventricular Canal, Rheumatoid Arthritis, Coronary Artery Disease, and Ischemic Cardiomyopathy. The exact mechanism of action of Allogeneic Mesenchymal Precursor Cells is currently unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Allogeneic Mesenchymal Precursor Cells |
|---|---|
| Sponsor | Mesoblast, Ltd. |
| Drug class | Cell therapy |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
These cells secrete anti-inflammatory cytokines and growth factors that modulate immune cell function, reduce pro-inflammatory signaling, and promote tissue repair. They interact with immune cells to suppress excessive inflammatory responses without broadly suppressing the immune system.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure (PHASE3)
- Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle (PHASE1, PHASE2)
- Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain (PHASE3)
- Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction (PHASE2)
- Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain (PHASE2)
- A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor (PHASE2)
- Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes (PHASE1, PHASE2)
- A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allogeneic Mesenchymal Precursor Cells CI brief — competitive landscape report
- Allogeneic Mesenchymal Precursor Cells updates RSS · CI watch RSS
- Mesoblast, Ltd. portfolio CI
Frequently asked questions about Allogeneic Mesenchymal Precursor Cells
What is Allogeneic Mesenchymal Precursor Cells?
How does Allogeneic Mesenchymal Precursor Cells work?
Who makes Allogeneic Mesenchymal Precursor Cells?
What drug class is Allogeneic Mesenchymal Precursor Cells in?
What development phase is Allogeneic Mesenchymal Precursor Cells in?
Related
- Drug class: All Cell therapy drugs
- Manufacturer: Mesoblast, Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing